Investor Relations

Corporate Profile

Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS).

Change

Volume

52 Week High

52 Week Low

Apr 2, 2020 12:31 AM EDT

News Releases

Mirum Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

March 12, 2020

New Drug Application Rolling Submission for Alagille Syndrome Planned to Begin in Third Quarter 2020 Cash, Cash Equivalents and Investments Balance of $140.0 million before gross proceeds of $48.0 million from a follow-on public offering in January 2020 On Track for PFIC Phase 3 Top-Line Data and

Mirum Pharmaceuticals to Participate at Four Upcoming Conferences

February 18, 2020

FOSTER CITY, Calif. --(BUSINESS WIRE)--Feb. 18, 2020-- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that company management will

Mirum Pharmaceuticals Promotes Ian Clements to Chief Financial Officer

January 14, 2020

FOSTER CITY, Calif. --(BUSINESS WIRE)--Jan. 14, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced the promotion of Ian Clements to Chief Financial

Mirum Pharmaceuticals Announces Pricing of Public Offering

January 8, 2020

FOSTER CITY, Calif. --(BUSINESS WIRE)--Jan. 8, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced the pricing of its public offering of 2,400,000 shares

Events

Raymond James 41st Annual Institutional Investors Conference

Mar 4, 2020 at 9:15 AM EST

Listen to webcast

Cowen 40th Annual Healthcare Conference

Mar 2, 2020 at 2:10 PM EST

Listen to webcast

SVB Leerink 9th Annual Global Healthcare Conference

Feb 26, 2020 at 9:30 AM EST

Listen to webcast

Investor Relations

Investor Relations

Corporate Profile

Header Menu